Granisetron HCl5-HT3 receptor antagonist CAS# 107007-99-8 |
- Vilazodone
Catalog No.:BCC2040
CAS No.:163521-12-8
- SB 271046 hydrochloride
Catalog No.:BCC1924
CAS No.:209481-24-3
- Adoprazine
Catalog No.:BCC1329
CAS No.:222551-17-9
- SEA0400
Catalog No.:BCC1941
CAS No.:223104-29-8
- Tianeptine
Catalog No.:BCC1999
CAS No.:66981-73-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 107007-99-8 | SDF | Download SDF |
| PubChem ID | 65264 | Appearance | Powder |
| Formula | C18H25ClN4O | M.Wt | 348.87 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | BRL 43694;Granisetron hydrochloride | ||
| Solubility | DMSO : 7.69 mg/mL (22.04 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 1-Methyl-N-[(3-endo)-9-methyl-9-aza | ||
| SMILES | [H+].[Cl-].CN1C2CCCC1CC(C2)NC(=O)c3nn(C)c4ccccc34 | ||
| Standard InChIKey | QYZRTBKYBJRGJB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H24N4O.ClH/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17;/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Granisetron Hcl(BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. IC50 Value: 17uM (GR reduced 5-HT-evoked contractions) Target: 5-HT3 receptor in vitro: In rat forestomach GR reduced 5-HT-evoked contractions at IC50 17 /- 6 uM. In isolated rabbit heart, GR 0.003-0.03 nM dose-dependently reduced s-HT tachycardia; at high levels GR reduced submaximal and maximal responses to 5-HT . in vivo: Leukocyte accumulation was dose-dependently inhibited by granisetron both at 6 and 72 h after induction of inflammation. Granisetron increased PGE(2) level at a lower dose (50 microg/pouch) but higher doses (100 and 200 microg/pouch) inhibited the release. At the same time, TNFalpha production was decreased by the lower dose and increased by higher doses of granisetron in a reciprocal fashion . The GTDS displayed non-inferiority to oral granisetron: complete control was achieved by 60% of patients in the GTDS group, and 65% in the oral granisetron group (treatment difference, -5%; 95% confidence interval, -13-3). Both treatments were well tolerated, the most common adverse event being constipation . Clinical trial: Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects. Phase 1 | |||||
Granisetron HCl Dilution Calculator
Granisetron HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8664 mL | 14.332 mL | 28.664 mL | 57.3279 mL | 71.6599 mL |
| 5 mM | 0.5733 mL | 2.8664 mL | 5.7328 mL | 11.4656 mL | 14.332 mL |
| 10 mM | 0.2866 mL | 1.4332 mL | 2.8664 mL | 5.7328 mL | 7.166 mL |
| 50 mM | 0.0573 mL | 0.2866 mL | 0.5733 mL | 1.1466 mL | 1.4332 mL |
| 100 mM | 0.0287 mL | 0.1433 mL | 0.2866 mL | 0.5733 mL | 0.7166 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
5-HT3 receptor antagonist that possesses potent antiemetic activity.
- Sarcosine
Catalog No.:BCN2744
CAS No.:107-97-1
- H-ß-Ala-OH
Catalog No.:BCC2851
CAS No.:107-95-9
- 3-Methyl-1-butylamine
Catalog No.:BCN1810
CAS No.:107-85-7
- N-Methyltaurine
Catalog No.:BCN1751
CAS No.:107-68-6
- Betaine
Catalog No.:BCN6303
CAS No.:107-43-7
- Taurine
Catalog No.:BCN1750
CAS No.:107-35-7
- Propylamine
Catalog No.:BCN1814
CAS No.:107-10-8
- Boc-isoleucinol
Catalog No.:BCC3096
CAS No.:106946-74-1
- Adefovir
Catalog No.:BCC8808
CAS No.:106941-25-7
- Boc-D-Leucinol
Catalog No.:BCC2723
CAS No.:106930-51-2
- Valproic acid sodium salt (Sodium valproate)
Catalog No.:BCC2156
CAS No.:1069-66-5
- 5-Allyl-3-methoxy-6-methyl-7-(3,4,5-trimethoxyphenyl)bicyclo[3.2.1]oct-3-ene-2,8-dione
Catalog No.:BCN1632
CAS No.:106894-43-3
- Amyloid Beta-Peptide (12-28) (human)
Catalog No.:BCC1044
CAS No.:107015-83-8
- O-Phosphorylethanolamine
Catalog No.:BCN1759
CAS No.:1071-23-4
- EIT hydrobromide
Catalog No.:BCC6824
CAS No.:1071-37-0
- Apo-12'-Lycopenal
Catalog No.:BCC8298
CAS No.:1071-52-9
- Adipic dihydrazide
Catalog No.:BCC8810
CAS No.:1071-93-8
- 8,9-Dihydroxy-10-isobutyryloxythymol
Catalog No.:BCN7974
CAS No.:107109-97-7
- Perindopril Erbumine
Catalog No.:BCC3586
CAS No.:107133-36-8
- Pyrocincholic acid methyl ester
Catalog No.:BCN5873
CAS No.:107160-24-7
- MAC13243
Catalog No.:BCC1727
CAS No.:1071638-38-4
- Deoxyflindissone
Catalog No.:BCN7268
CAS No.:107176-31-8
- AT-406 (SM-406)
Catalog No.:BCC1283
CAS No.:1071992-99-8
- Epigoitrin
Catalog No.:BCN6278
CAS No.:1072-93-1
Hydrophilic interaction liquid chromatography in analysis of granisetron HCl and its related substances. Retention mechanisms and method development.[Pubmed:26895494]
J Pharm Biomed Anal. 2016 May 10;123:93-103.
In this paper separation of granisetron and its two related substances in HILIC mode is presented. Separation was done on silica column derivatized with sulfoalkylbetaine groups (ZIC-HILIC). Firstly, retention mechanisms were assessed whereby retention factors of substances were followed in wide range of acetonitrile content (80-97%), at constant concentration of aqueous buffer (10mM) as well as at constant pH value of 3.0. Further, in order to developed optimal HILIC method, Design of Experiments (DoE) methodology was applied. For optimization full factorial design 3(2) was employed. Influence of acetonitrile content and ammonium acetate concentration were investigated while pH of the water phase was kept at 3.3. Adequacy of obtained mathematical models was confirmed by ANOVA. Optimization goals (alpha>1.15 and minimal run time) were accomplished with 94.7% of acetonitrile in mobile phase and 70 mM of ammonium acetate in water phase. Optimal point was in the middle of defined Design Space. In the next phase, robustness was experimetally tested by Rechtschaffen design. The investigated factors and their levels were: acetonitrile content (+/-1%), ammonium acetate molarity in water phase (+/-2 mM), pH value of water phase (+/-0.2) and column temperature (+/-4 degrees C). The validation scope included selectivity, linearity, accuracy and precision as well as determination of limit of detection (LOD) and limit of quantification (LOQ) for the related substances. Additionally, the validation acceptance criteria were met in all cases. Finally, the proposed method could be successfully utilized for estimation of Granisetron HCl and its related substances in tablets and parenteral dosage forms, as well as for monitoring degradation under various stress conditions.
Formulation of Convenient, Easily Scalable, and Efficient Granisetron HCl Intranasal Droppable Gels.[Pubmed:25936630]
Mol Pharm. 2015 Jun 1;12(6):2019-25.
Deacetylated gellan gum and two sodium alginate polymer types were used each at three concentrations in the suitable range for their sol-gel transition. The prepared nine droppable gels were evaluated in vitro, ex vivo through sheep nasal mucosa, as well as in vivo in comparison to drug solution given intravenously and orally at the same dose. The prepared formulas gelled instantaneously in simulated nasal fluid and the obtained gels sustained their shear thinning and thixotropic behavior up to 48 h. Polymer type and concentration had significant effects on the apparent viscosities and the in vitro release profile of granisetron from the prepared gels. The drug release data best fitted a modified Higuchi equation with initial burst and followed Fickian diffusion mechanism. A 0.5% gellan-gum-based formula sustained the in vitro drug release up to 3 h and enhanced the drug permeation without need for an enhancer. The histopatholgical study revealed the safety of the tested formula. Intranasal delivery recorded double the drug bioavailabilty in comparison to the oral route. It had an absolute bioavailability of 0.6539 and the maximum plasma drug concentration reached after 1.5 h. The developed formula could be promising for the management of chemotherapy-induced nausea and vomiting regarding its improved bioavailability, patient acceptability, and ease of production.
Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.[Pubmed:1723376]
Drugs. 1991 Nov;42(5):805-24.
Granisetron (BRL 43694) is a highly selective 5-HT3 receptor antagonist which possesses significant antiemetic activity, likely mediated through antagonism of 5-HT3 receptors on abdominal vagal afferents and possibly in or near the chemoreceptor trigger zone. Clinical trials in cancer patients demonstrate that, compared with placebo, granisetron significantly reduces the incidence of nausea and vomiting for 24 hours after administration of high-dose cisplatin. In large comparative trials, 70% of patients who received granisetron prior to cisplatin or other chemotherapy experienced complete inhibition of vomiting with little or no nausea for 24 hours after antineoplastic administration; these results were similar to those obtained with high-dose metoclopramide plus dexamethasone, and superior to a combination of chlorpromazine plus dexamethasone, or prochlorperazine plus dexamethasone, or methylprednisolone monotherapy. The most frequently reported adverse event associated with granisetron administration is headache which occurs in about 10 to 15% of patients while constipation, somnolence, diarrhoea and minor transient changes in blood pressure have been reported less frequently. Extrapyramidal effects, which can occur with high-dose metoclopramide and may be a limiting factor in its use, have not been noted with granisetron administration. Thus, granisetron is an effective, well tolerated and easily administered agent for the prophylaxis of nausea and vomiting induced by cancer chemotherapy which appears to be devoid of extrapyramidal side effects associated with metoclopramide. As a member of a new class of drugs, the selective 5-HT3 receptor antagonists, granisetron provides the medical oncologist with a new, potentially more acceptable antiemetic therapy.
Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron).[Pubmed:2540014]
Eur J Pharmacol. 1989 Jan 10;159(2):113-24.
The activity of BRL 43694 (granisetron) was investigated using established models of 5-HT3 receptor activity. In guinea-pig isolated ileum, BRL 43694 antagonised the contractions evoked by relatively high concentrations of 5-HT (pA2 = 8.1 +/- 0.2). However, except in high concentrations, BRL 43694 did not affect the contractions of similar preparations of ileum, evoked by electrical field stimulation (cholinergically mediated), the nicotinic agonist dimethylphenyl piperazinium (DMPP) or by cholecystokinin octapeptide. Similarly, BRL 43694 did not affect electrically evoked, cholinergically mediated contractions of rat or human isolated stomach. In other models of 5-HT3 receptor activity (rabbit isolated heart, Bezold-Jarisch reflex in anaesthetised rats), potent antagonism by BRL 43694 was demonstrated. In radioligand binding studies on rat brain membranes, BRL 43694 had little or no affinity for 5-HT1A, 5-HT1B, 5-HT2 or for many other binding sites. BRL 43694 may therefore be a potent and selective 5-HT3 receptor antagonist.
